Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: gemcitabine hydrochloride, gallium nitrate, gti-2040 +7 | 1.00 |
| trials ClinicalTrials.gov | 17 Parkinson's trials, 3 stopped | 0.86 |
| literature PubMed | 6 Parkinson's papers of 1,263 | 0.74 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 9830
Sealed predictions
- RRM2 in dopamine neurons, braak-0.16 (p 0.680) → +0.37 (p 0.323)receipt 9838
Swarm cases
receipt 9838: RRM2 in dopamine neurons, braak
- power
- full sample -0.03 (p 0.908, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.08 (p 0.767, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.07 (p 0.794, n 18). could be the mix.
- skeptic
- leave-one-out range -0.14 to +0.10, sign flips 5; without severely affected donors -0.03 (p 0.908, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RRM2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts